Gilead news and events in 2026
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine.
Public (GILD)Biotechnology Research10,000+ employeesgilead.comLinkedIn
- Dated updates
- 64
- Last event
- Sep 29, 2026
- Open rolesSnapshot Sep 29, 2026
- 89
- Latest SEC filing
- Aug 6, 2026
Overview
Gilead by topic
110-K filing
48-K filings
89open roles
1reported layoff round
1executive move
40+signals
27 in the last 90 days
- Glassdoor15+
- Website changes9
- Employee growth7
- Patents6
- and 2 more sources
Latest events
Latest Gilead events
Showing 10 of 17 events. The Signal API returns all of them.
Get them with one API call- New location
- Facility expansionGilead opens new building on existing Foster City campusGilead Sciences unveiled a new 182,000 square-foot building on its existing campus in Foster City, which will house oncology and scientific research.
- In developmentGilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?Gilead Sciences is developing Yeztugo, a once-weekly oral HIV pre-exposure prophylaxis (PrEP) with a PDUFA target date of Feb. 2.
- Partnership
- LaunchFDA approves daily HIV pill from Gilead designed to simplify treatment for some patientsGilead Sciences launched its new once-daily HIV pill, Bixlenvo, after receiving approval from the U.S. Food and Drug Administration.
- EarningsGilead's Second-Quarter Revenue Rises 8%, Exceeding Wall Street ForecastsGilead Sciences reported an adjusted loss per share of $6.75 for the second quarter, better than the analyst consensus expectation of a $7.24 loss.
- LaunchWill the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?Gilead Sciences received FDA approval for the label expansion of its breast cancer drug Trodelvy for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).
- In development
- PartnershipPharmaceutical Executive Daily: what it takes to move machine learning.With World Health Organization International
- Layoff
Showing 10 of 17 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Gilead with the Signal API
One POST /v1/companies/enrich call with gilead.com returns every signal type for Gilead, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","limit":20}'Same industry
Companies related to Gilead
Gilead questions
What is the latest news on Gilead?
What is going on with Gilead?
Is Gilead laying off employees?
What else does Autobound track for Gilead?
Is Gilead hiring right now?
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .